Histone deacetylases in the regulation of cell death and survival mechanisms in resistant BRAF-mutant cancers
{{output}}
Small-molecule BRAF inhibitors (e.g., vemurafenib and dabrafenib) and MEK (MAPK/ERK) kinases inhibitors (e.g., trametinib) have distinctly improved the survival of patients suffering from BRAF-mutant cancers such as melanomas. However, the emergence of resista... ...
